Indeed, in complex karyotype AML patients with functional TP53, upregulation of miR-34a associates with shorter overall survival, whereas in patients with impaired TP53, it associates with longer overall survival and chemotherapy sensitivity [67]. The gene discussed is TP53; the disease is acute myeloid leukemia.